IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct two phase I clinical trials

In early November, IPHARMA, a company of ChemRar Group, received two approvals from the Ministry of Healthcare of the Russian Federation to conduct phase I clinical trials of Ventvil® and Slavinorm®.

Protocol No. HEP-VTL-01 “A double-blind, randomized, placebo-controlled trial of the safety and tolerability of increasing doses of Ventvil® in single and subsequent repeated intramuscular administration in healthy volunteers”.

The study aim: to evaluate the safety and tolerability of increasing doses of the drug in single and subsequent multiple intramuscular administration in healthy volunteers.

Area of application: therapy, hepatic disorders.

Protocol No. CNS-SNM-01 “A double-blind, randomized, placebo-controlled trial of the safety and tolerability of increasing doses of Slavinorm® in single and subsequent multiple intramuscular administration in healthy volunteers”.

The study aim: to evaluate the safety and tolerability of increasing doses of the drug in single and subsequent multiple intramuscular administration in healthy volunteers.

Area of application: neurology (angioprotector).

Ventvil® and Slavinorm® are developed by SIA Peptides. It is a complex of polypeptides extracted from the organs and horns of cattle.